Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease, characterized by degeneration of the anterior horn cells of the spinal cord. SMA presents with a highly variable phenotype ranging from very severe to mild (type I–III). No cure for SMA is available at present. All forms of SMA are caused by homozygous loss of the functional survival motor neuron (SMN1) gene. However, all patients have one or more copies of the SMN2 gene, nearly identical to SMN1. Both genes encode the SMN protein but the level produced by SMN2 is insufficient to protect from disease. Increasing SMN2 gene expression could be of considerable therapeutic importance. The aim of this study was to assess whether SMN2 gene expression can be increased by 4-phenylbutyrate (PBA). Fibroblast cell cultures from 16 SMA patients affected by different clinical severities were treated with PBA, and full-length SMN2 transcripts were measured by real-time PCR. In all cell cultures, except one, PBA treatment caused an increase in full-length SMN2 transcripts, ranging from 50 to 160% in type I and from 80 to 400% in type II and III cultures. PBA was found also effective in enhancing SMN protein levels and the number of SMN-containing nuclear structures (gems). These data show that SMN expression is considerably increased by PBA, and suggest that the compound, owing also to its favorable pharmacological properties, could be a good candidate for the treatment of SMA.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Lefebvre S, Bürglen L, Reboullet S et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–165.
Lorson CL, Hahnen E, Androphy EJ, Wirth B : A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 96: 6307–6311.
Monani UR, Lorson CL, Parsons DW et al: A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN. Hum Mol Genet 1999; 8: 1177–1183.
McAndrew PE, Parsons DW, Simard LR et al: Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNt and SMNc gene copy number. Am J Hum Genet 1997; 69: 1411–1422.
Vitali T, Sossi V, Tiziano F et al: Detection of the survival motor neuron (SMN) genes by FISH: further evidence for a role of SMN2 in the modulation of disease severity in SMA patients. Hum Mol Genet 1999; 8: 2525–2532.
Brahe C : Copies of the survival motor neuron gene in spinal muscular atrophy: the more, the better. Neuromusc Disord 2000; 10: 274–275.
Feldkötter M, Schwarzer V, Wirth R, Wienker TI, Wirth B : Quantitative analysis of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70: 358–368.
Liu Q, Dreyfuss G : A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996; 15: 3555–3565.
Lefebvre S, Burlet P, Liu Q et al: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16: 265–269.
Coovert DD, Le TT, McAndrew PE et al: The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 1997; 6: 1205–1214.
Patrizi AL, Tiziano F, Zappata S, Donati A, Neri G, Brahe C : SMN protein analysis in fibroblast, amniocyte, and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis. Eur J Hum Genet 1999; 7: 301–309.
Miller RG, Moore DH, Dronsky V et al: A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001; 191: 127–131.
Tzeng AC, Cheng J, Fryczynski H et al: A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil 2000; 79: 435–440.
Kinali M, Mercuri E, Main M et al: Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002; 59: 609–610.
Baron-Delage S, Abadie A, Echaniz-Laguna A, Melki J, Beretta L : Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 2000; 6: 957–968.
Andreassi C, Jarecki J, Zhou J et al: Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10: 2841–2849.
Chang J-G, Hsieh-Li H-M, Jong Y-J, Wang NM, Tsai C-H, Li H : Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98: 9808–9813.
Vitali T, Tiziano F, Neri G, Brahe C : SMN2 gene activation by sodium butyrate and acetyl-L-carnitine in cell cultures from SMA patients; Abstract, Fifth Annual North American/International Spinal Muscular Atrophy Research and Clinical Meeting; June 22–24, 2001; Chicago.
Tiziano FD, Andreassi C, Angelozzi C et al: Upregulation of SMN2 gene expression by 4-phenylbutyrate: relevance for a therapeutic approach to spinal muscular atrophy. Am J Hum Genet 2002; 71 (Suppl): A2445.
Maestri NE, Brusilow SW, Clissold DB, Bassett S : Long term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996; 335: 855–859.
Gilbert J, Baker SD, Bowling MK et al: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292–2300.
Davis T, Kennedy C, Chiew Y-E, Clarke CL, deFazio A : Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res 2000; 6: 4334–4342.
McGrath-Morrow SA, Stahl JL : G1 phase growth arrest and induction of p21waf1/Cip/Sdi1 in IB3-1 cells treated with 4-sodium phenylbutyrate. J Pharmacol Exp Therap 2000; 294: 941–947.
Dover GJ, Brusilow S, Charache S : Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium pehylbutyrate. Blood 1994; 84: 339–343.
Gore SD, Samid D, Weng L-J : Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997; 3: 1755–1762.
Carducci MA, Nelson JB, Chantack KM et al: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996; 2: 379–387.
Brusilow SW, Maestri NE : Urea cycle disorders: diagnosis, pathophysiology and therapy. Adv Pediat 1996; 23: 127–170.
Kemp S, Wei H-M, Lu J-F et al: Gene redundancy of pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 1998; 4: 1261–1268.
Berg S, Serabe B, Aleksic A et al: Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol 2001; 47: 385–390.
Acknowledgements
We thank the families for their kind cooperation and are grateful to Dr A Valenza for his help in densitometric scanning of the autoradiograms and to Professor G D'Abramo for his help in statistical analysis. The study was supported by grants from the Associations ASAMSI and Italian Families of SMA, Telethon and MURST 60%.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andreassi, C., Angelozzi, C., Tiziano, F. et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12, 59–65 (2004). https://doi.org/10.1038/sj.ejhg.5201102
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.ejhg.5201102
Keywords
This article is cited by
-
Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy
Scientific Reports (2023)
-
Therapeutic potential of endoplasmic reticulum stress inhibitors in the treatment of diabetic peripheral neuropathy
Metabolic Brain Disease (2023)
-
Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy
Neurotherapeutics (2013)
-
Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein
Molecular Neurobiology (2013)
-
Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study
European Journal of Human Genetics (2013)
